Bionomics Limited (BNOEF)
Bionomics Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Eastwood, SA, AU. The stock last traded at $0.01, down 14.89% on the session, giving a market capitalisation of $8.8M. On trailing twelve-month figures it carries a trailing P/E of -0.50, a net margin of -1578.4%. Its beta of 1.84 implies it has historically moved more than the broad market.
Bionomics Limited, an Australian clinical-stage biopharmaceutical company founded in 1996 and based in Eastwood, focuses on identifying and developing innovative drug candidates to address central nervous system conditions and various cancers. A significant experimental medicine in their pipeline is BNC210, a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor. This compound is currently undergoing a Phase 2 clinical trial for social anxiety disorder and a Phase 2b study for post-traumatic stress disorder (PTSD). The company's portfolio also includes BNC101, a monoclonal antibody designed to combat cancer stem cells, which has successfully completed its Phase 1 clinical evaluation. Additionally, Bionomics is advancing BNC105, currently in a Phase 2 clinical trial for refractory colorectal cancer and a Phase 1 trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Bionomics Limited is most often compared with the following Healthcare names: